Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

Therapies such as BRAF inhibitors have become standard treatment for melanoma patients whose tumors harbor activating BRAF(V600) mutations. However, analogous therapies for inhibiting NRAS mutant signaling have not yet been well established. In this study, we performed an integrative analysis of DNA...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385866/
https://ncbi.nlm.nih.gov/pubmed/25537510
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares